VCU Massey Cancer Center | Strategic Alliance Partners

A National Cancer Institute-designated cancer center in Richmond, Va., VCU Massey Cancer Center conducts basic, translational, clinical and population sciences cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer.

Latest from VCU Massey Cancer Center


Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management

September 19, 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

Dr. Geyer on Impact of Targeted Agents in HER2+ Breast Cancer

January 22, 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

December 29, 2018

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer

December 11, 2018

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.

x